Taskforce recommendations for remdesivir unchanged following detailed analysis of disease severity subgroups
The National COVID-19 Clinical Evidence Taskforce, of which the College is a member, has completed a comprehensive review to assess the credibility of disease severity subgroups used in its recommendations on remdesivir. This was initiated following the World Health Organisation (WHO) decision to make a conditional recommendation against the use of remdesivir in all hospitalised patients, regardless of disease severity (20 November 2020). This differs from the Taskforce conditional recommendation supporting use in hospitalised adults with moderate to severe COVID-19 who do not require ventilation (invasive or non-invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)).
The review by the Disease-Modifying Treatment and Chemoprophylaxis Panel and Guidelines Leadership Group, with additional input from virologists and immunologists, concludes that there are several factors that contribute to differences in recommendations between WHO and the Taskforce:
A detailed methods brief outlines the steps taken in this review.
Read the Taskforce's weekly communique here.